Antitumor effect of cetuximab in combination with S-1 in EGFR-amplified gastric cancer cells

International Journal of Oncology

Volumn 40, Issue 4, 2012, Pages 975-982

  Fukuda, Kazumasa ^a   Saikawa, Yoshiro ^a   Takahashi, Masashi ^a   Takahashi, Tsunehiro ^a   Wada, Norihito ^a   Kawakubo, Hirohumi ^a   Takeuchi, Hiroya ^a   Kitagawa, Yuko ^a  

^a KEIO UNIVERSITY   (Japan)

Author keywords

Cetuximab; Combination therapy; Gastric cancer; Human epidermal growth factor receptor; S 1

Indexed keywords

CETUXIMAB; GIMERACIL PLUS OTERACIL POTASSIUM PLUS TEGAFUR; VASCULOTROPIN RECEPTOR;

ANIMAL CELL; ANIMAL CELL CULTURE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BODY WEIGHT; CANCER COMBINATION CHEMOTHERAPY; CELL MEMBRANE; CONTROLLED STUDY; CYTOPLASM; DRUG EFFICACY; DRUG POTENTIATION; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; MALE; MITOSIS INHIBITION; MONOTHERAPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; STOMACH CANCER; TUMOR VOLUME; TUMOR XENOGRAFT;

ADULT; AGED; AGED, 80 AND OVER; ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; COMBINED MODALITY THERAPY; DRUG COMBINATIONS; FEMALE; FLUOROURACIL; GENE AMPLIFICATION; HUMANS; MALE; MICE; MICE, NUDE; MIDDLE AGED; OXONIC ACID; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION; STOMACH NEOPLASMS; TEGAFUR; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84863389751     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2011.1279     Document Type: Article

References (35)

1. Jemal A, Siegel R, Ward E, et al: Cancer statistics, 2008. CA Cancer J Clin 58: 71-96, 2008. (Pubitemid 351521864)
2. Mari E, Floriani I, Tinassi A, et al: Efficacy of adjuvant chemotherapy after curative resection for gastric cancer: a meta-analysis of published randomized trials. Ann Oncol 11: 837-843, 2000.
3. Panzini I, Gianni L, Fattori PP, et al: Adjuvant chemotherapy in gastric cancer: a meta-analysis of randomized trials and a comparison with previous meta-analyses. Tumori 88: 21-27, 2002. (Pubitemid 34269794)
4. Sakata Y, Ohtsu A, Horikoshi N, Sugimachi K, Mitachi Y and Taguchi T: Late phase II study of novel oral fluoropyrimidine anticancer drug S-1 (1 M tegafur-0.4 M gimestat-1 M otastat potassium) in advanced gastric cancer patients. Eur J Cancer 34: 1715-1720, 2008.
5. Koizumi W, Kurihara M, Nakano S and Hasegawa K: Phase II study of S-1, a novel oral derivative of 5-fluorouracil, in advanced gastric cancer. For the S-1 Cooperative Gastric Cancer Study Group. Oncology 58: 191-197, 2000. (Pubitemid 30189900)
6. Koizumi W, Narahara H, Hara T, et al: S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. Lancet Oncol 9: 215-221, 2008.
7. Sakuramoto S, Sasako M, Yamaguchi T, et al: Adjuvant chemotherapy for gastric cancer with S-1 an oral fluoropyrimidine. N Engl J Med 357: 1810-1820, 2007. (Pubitemid 350044801)
8. Boku N: Chemotherapy for metastatic disease: review from JCOG trials. Int J Clin Oncol 13: 196-200, 2008.
9. Hartgrink HH, Jansen EP, van Grieken NC and van de Velde CJ: Gastric cancer. Lancet 374: 477-490, 2009.
10. Wesolowski R, Lee C and Kim R: Is there a role for second-line chemotherapy in advanced gastric cancer? Lancet Oncol 10: 903-912, 2009.
11. Ferrara N and Kerbel RS: Angiogenesis as a therapeutic target. Nature 438: 967-974, 2005. (Pubitemid 43093963)
12. Iqbal S, Goldman B, Fenoglio-Preiser CM, Lenz HJ, Zhang W, Danenberg KD, Shibata SI and Blanke CD: Southwest Oncology Group study S0413: a phase II trial of lapatinib (GW572016) as first-line therapy in patients with advanced or metastatic gastric cancer. Ann Oncol: May 20, 2011 (Epub ahead of print).
13. Cappetta A, Lonardi S, Pastorelli D, Bergamo F, Lombardi G and Zagonel V: Advanced gastric cancer (GC) and cancer of the gastro-oesophageal junction (GEJ): focus on targeted therapies. Crit Rev Oncol Hematol: Jan 19, 2011 (Epub ahead of print).
14. Cunningham D, Humblet Y, Siena S, et al: Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 351: 337-345, 2004. (Pubitemid 38944402)
15. Saltz LB, Meropol NJ, Loehrer PJ Sr, Needle MN, Kopit J and Mayer RJ: Phase II trial of cetuximabin patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol 22: 1201-1208, 2004. (Pubitemid 41079832)
16. Chou TC and Talalay P: Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 22: 27-55, 1984.
17. Yarden Y and Sliwkowski MX: Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2: 127-137, 2001. (Pubitemid 33674041)
18. Carpenter G and Cohen S: Epidermal growth factor. J Biol Chem 265: 7709-7712, 1999.
19. Bonner JA, Harari PM, Giralt J, et al: Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 354: 567-578, 2006. (Pubitemid 43209104)
20. Vermorken JB, Mesia R, Rivera F, et al: Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med 359: 1116-1127, 2008.
21. Hanna N, Lilenbaum R, Ansari R, et al: Phase II trial of cetuximab in patients with previously treated non-small cell lung cancer. J Clin Oncol 24: 5253-5258, 2006. (Pubitemid 46631370)
22. Lee JC, Wang ST, Chow NH and Yang HB: Investigation of the prognostic value of coexpressed erbB family members for the survival of colorectal cancer patients after curative surgery. Eur J Cancer 38: 1065-1071, 2002. (Pubitemid 34468011)
23. Porebska I, Harlozinska A and Bojarowski T: Expression of the tyrosine kinase activity growth factor receptors (EGFR, ERBB2, ERBB3) in colorectal adenocarcinomas and adenomas. Tumor Biol 21: 105-115, 2002. (Pubitemid 30114656)
24. Bancroft CC, Chen Z, Yeh J, et al: Effects of pharmacologic antagonists of epidermal growth factor receptor, PI3K and MEK signal kinases on NF-κB and AP-1 activation and IL-8 and VEGF expression in human head and neck squamous cell carcinoma lines. Int J Cancer 99: 538-548, 2002. (Pubitemid 34461606)
25. Raymond E, Fauvre S and Armand JP: Epidermal growth factor receptor tyrosine kinase as a target for anticancer therapy. Drugs 60 (Suppl 1): S15-S23, 2000.
26. Baselga J, Norton L, Masui H, Pandiella A, Coplan K, Miller WH and Mendelsohn J: Antitumor effects of doxorubicin in combination with anti-epidermal growth factor receptor monoclonal antibodies. J Natl Cancer Inst 85: 1327-1333, 1993. (Pubitemid 23249725)
27. Bruns CJ, Harbison MT, Davis DW, et al: Epidermal growth factor receptor blockade with cetuximab plus gemcitabine results in regression of human pancreatic carcinoma growing orthotopically in nude mice by antiangiogenic mechanisms. Clin Cancer Res 6: 1936-1948, 2006.
28. Ciardiello F, Bianco R, Damiano V, et al: Antitumor activity of sequential treatment with topotecan and anti-epidermal growth factor receptor monoclonal antibody C225. Clin Cancer Res 4: 909-916, 1999.
29. Fan Z, Baselga J, Masui H and Mendelsohn J: Antitumor effect of anti-EGF receptor monoclonal antibodies plus cis-diamminedichloroplatinum (cis-ddp) on well established A431 cell xenografts. Cancer Res 53: 4637-4642, 1993. (Pubitemid 23304392)
30. Huang SM, Bock JM and Harari PM: Epidermal growth factor receptor blockade with C225 modulates proliferation, apoptosis, and radiosensitivity in squamous cell carcinomas of the head and neck. Cancer Res 59: 1935-1940, 1999. (Pubitemid 29186168)
31. Huang SM and Harari PM: Modulation of radiation response after epidermal growth factor receptor blockade in squamous cell carcinomas: inhibition of damage repair, cell cycle kinetics, and tumor angiogenesis. Clin Cancer Res 6: 2166-2174, 2000.
32. Inoue K, Slaton JW, Perrotte P, et al: Paclitaxel enhances the effects of the anti-epidermal growth factor receptor monoclonal antibody ImClone C225 in mice with metastatic human bladder transitional cell carcinoma. Clin Cancer Res 6: 4874-4884, 2000. (Pubitemid 32110432)
33. Prewett MC, Hooper AT, Bassi R, Ellis LM, Waksal HW and Hicklin DJ: Enhanced antitumor activity of anti-epidermal growth factor receptor monoclonal antibody IMCC225 in combination with irinotecan (CPT-11) against human colorectal tumor xenografts. Clin Cancer Res 8: 994-1003, 2002. (Pubitemid 34517632)
34. Shin DM, Donato NJ, Perez-Soler R, et al: Epidermal growth factor receptor-targeted therapy with C225 and cisplatin in patients with head and neck cancer. Clin Cancer Res 7: 1204-1213, 2001. (Pubitemid 32708671)
35. Han SW, Oh DY, Im SA, Park SR, Lee KW, Bang YJ and Kim TY: Phase II study and biomarker analysis of cetuximab combined with modified FOLFOX6 in advanced gastric cancer. Br J Cancer 100: 298-304, 2009.